NCT04130204View on ClinicalTrials.gov

Topical Application to Relieve Gout: Efficacy Trial & Safety (TARGETS)

PHASE2CompletedINTERVENTIONAL
Enrollment

284

Participants

Timeline

Start Date

February 12, 2020

Primary Completion Date

May 21, 2021

Study Completion Date

May 21, 2021

Conditions
Gout
Interventions
DRUG

DYV700

Proprietary transdermal delivery platform

DRUG

Placebo

Vehicle transdermal delivery platform

DRUG

Colchicine 0.6 mg

Standard of care, 2 tablets (1.2 mg) loading dose followed by 1 tablet (0.6 mg) 1 hour later at onset of gout flare.

Trial Locations (1)

92064

Smitha Reddy, Poway

Sponsors
All Listed Sponsors
lead

Dyve Biosciences, Inc.

INDUSTRY